Adaptimmune Ther ADR (ADAP) Stock Price, Quote & News

Company Profile

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the t...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 12 3543 0000

Website: www.adaptimmune.com

Address:

60 Jubilee Avenue, Milton Park, Abingdon, United Kingdom

CATatom Oct. 25 at 1:49 PM

$ADAP T-cell pipeline still intact. Patents still active. Trials paused, not canceled. Delisting ≠ death. OTC opens Tuesday. Monday’s candle decides who believed early. ADAP will stop trading on the Nasdaq Capital Market after the close of trading on October 27, 2025. Starting October 28, 2025, its American Depositary Shares (ADSs) will be quoted on the OTC Pink Limited Market. Science doesn’t care about Nasdaq. Shorts played the fade. But they didn’t cover. Monday’s volume spike could trigger a reflexive squeeze.

3 · Reply

HellasManN10 Oct. 25 at 1:48 PM

$ADAP In my humble opinion, the voluntary abandonment of the Nasdaq could have been due to a combination of factors (need to save on costs, obligations, constraints, etc.) assuming a final solution such as a sale or merger, in the OTC the company probably she wanted to distance herself to feel freer about 1) HOW to proceed (with whom and in what manner) 2) HOW MUCH to sell and, above all 3) WHEN ... the timing factor is important ... === 》I have kept all my many shares

0 · Reply

SMARTR8 Oct. 25 at 1:43 PM

🚨 If you’re still only following me here, you’re missing out. The real plays, live discussions, and updates all happen inside the Discord — before anything ever gets posted on Stocktwits. THIS WEEK $SCNX from 0.56 to 2.98 $VSEE from 0.56 to 1.18 $ADAP from 0.05 to 0.092 - all shared for FREE We’re even running a Stock Pick Challenge this week — someone’s walking away with free VIP Vault access 💎. If you’re serious about trading smart, you’ll want to be in there before the next wave hits. 👉 Link in bio

0 · Reply

Gamaret Oct. 25 at 1:27 PM

$ADAP

0 · Reply

FlyAlways Oct. 25 at 12:38 PM

$ADAP has the potential for explosive moves 🧨

1 · Reply

US_Bull Oct. 25 at 12:27 PM

$ADAP Misery loves company those who bash and talk down the stock are the ones that sold at a 6-70% loss when they released the PR so they bought high and sold low lol. Company has hit the reset button, paid all debts, has a very promising preclinical pipeline in CD70 and PRAME and allogenic technology, and most importantly has the IP and know how to take the sold assets to approval. USWorldmed needs that know how still little grey area what happens to their PS with GLPG. I am assuming that PS may be put on a backburner as well since GLPG is winding down their cell therapy pipeline. A delisting of the stock is not the same as a company going bankrupt shocking how people are investing with their hard earned $ lol.

1 · Reply

Gamaret Oct. 25 at 9:49 AM

$ADAP

0 · Reply

Gamaret Oct. 25 at 9:33 AM

$ADAP Consider the example of SPRB Spruce Biosciences, Inc.

0 · Reply

Gamaret Oct. 25 at 9:28 AM

$ADAP Someone mentioned SPRB stock, which also ended up on the OTC market. I did some research: Spruce Biosciences, Inc.'s stock rose sharply after the FDA granted its drug Breakthrough Therapy Designation in October 2025. This designation allowed the company to move from an over-the-counter (OTC) listing to a listing on the Nasdaq Capital Market, which led to a sharp rise in the stock price due to investor optimism.

1 · Reply

stockCryptoHunter Oct. 24 at 11:51 PM

$ADAP Monday will be interesting .

1 · Reply

Adaptimmune Announces Delisting from Nasdaq

Aug 13, 2025, 7:30 AM EDT - 2 months ago

Adaptimmune Reports Q2 Financial Results and Provides Business Update

Jul 28, 2025, 7:30 AM EDT - 3 months ago

Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

May 13, 2025, 1:59 PM EDT - 5 months ago

Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 5 months ago

Adaptimmune Reports Q1 Financial Results and Provides Business Update

May 7, 2025, 12:00 PM EDT - 6 months ago

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

Mar 20, 2025, 12:10 PM EDT - 7 months ago

Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 7:00 AM EDT - 7 months ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update

Mar 12, 2025, 4:54 PM EDT - 8 months ago

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Jan 30, 2025, 4:00 PM EST - 9 months ago

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Jan 13, 2025, 8:00 AM EST - 10 months ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Dec 19, 2024, 7:30 AM EST - 11 months ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

Dec 2, 2024, 4:00 PM EST - 11 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

Nov 13, 2024, 7:48 PM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 1 year ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Nov 13, 2024, 9:00 AM EST - 1 year ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Nov 5, 2024, 9:19 AM EST - 1 year ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Oct 31, 2024, 5:20 PM EDT - 1 year ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Participate in Two Bank Conferences this September

Aug 12, 2024, 11:42 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Aug 2, 2024, 9:20 AM EDT - 1 year ago

US FDA approves Adaptimmune's gene therapy for rare type of cancer

Aug 1, 2024, 8:20 PM EDT - 1 year ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

Jul 3, 2024, 9:54 AM EDT - 1 year ago

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jun 17, 2024, 2:05 PM EDT - 1 year ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Jun 3, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

May 30, 2024, 4:01 PM EDT - 1 year ago

Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications

GLPG

May 30, 2024, 4:01 PM EDT - 1 year ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

GLPG

May 15, 2024, 10:07 AM EDT - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript

May 15, 2024, 7:30 AM EDT - 1 year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

May 15, 2024, 7:00 AM EDT - 1 year ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

HTGC

May 1, 2024, 12:00 PM EDT - 1 year ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Apr 26, 2024, 11:00 AM EDT - 1 year ago

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Mar 27, 2024, 7:30 PM EDT - 1 year ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Mar 6, 2024, 9:29 AM EST - 1 year ago

Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 1 year ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Feb 27, 2024, 8:00 AM EST - 1 year ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Feb 21, 2024, 4:00 PM EST - 1 year ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

Jan 31, 2024, 4:44 PM EST - 1 year ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Jan 4, 2024, 7:37 AM EST - 1 year ago

Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference

Dec 6, 2023, 7:00 AM EST - 2 years ago

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

Nov 29, 2023, 8:00 AM EST - 2 years ago

Adaptimmune Receives Transfer of IND for Lete-cel Program

Nov 8, 2023, 11:45 AM EST - 2 years ago

Adaptimmune Therapeutics plc (ADAP) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 7:30 AM EST - 2 years ago

Adaptimmune Reports Third Quarter Financial Results and Business Update

Nov 8, 2023, 7:05 AM EST - 2 years ago

Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control

Oct 25, 2023, 8:06 AM EDT - 2 years ago

Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023

CATatom Oct. 25 at 1:49 PM

3 · Reply

HellasManN10 Oct. 25 at 1:48 PM

0 · Reply

SMARTR8 Oct. 25 at 1:43 PM

0 · Reply

Gamaret Oct. 25 at 1:27 PM

$ADAP

0 · Reply

FlyAlways Oct. 25 at 12:38 PM

$ADAP has the potential for explosive moves 🧨

1 · Reply

US_Bull Oct. 25 at 12:27 PM

1 · Reply

Gamaret Oct. 25 at 9:49 AM

$ADAP

0 · Reply

Gamaret Oct. 25 at 9:33 AM

$ADAP Consider the example of SPRB Spruce Biosciences, Inc.

0 · Reply

Gamaret Oct. 25 at 9:28 AM

1 · Reply

stockCryptoHunter Oct. 24 at 11:51 PM

$ADAP Monday will be interesting .

1 · Reply

Thunder000 Oct. 24 at 11:31 PM

$ASST $VIVK $ADAP CLIK is running but I’d say no to Chinese Hong Kong companies, I chose to stick with American dear darling lovely ones💪

0 · Reply

Wildblitz Oct. 24 at 11:27 PM

$ADAP $HCTI $TELO - my 3 craptastic stocks of the week

0 · Reply

btball64 Oct. 24 at 10:32 PM

$ADAP Will there be a new stock ticker on Monday?

1 · Reply

berat2209 Oct. 24 at 10:14 PM

$ADAP do you think US WorldMeds will acquire this company

2 · Reply

RedHottie Oct. 24 at 9:36 PM

$ADAP nice candle

1 · Reply

RedHottie Oct. 24 at 9:29 PM

$ADAP Green 🤗

0 · Reply

RedHottie Oct. 24 at 9:18 PM

$ADAP OK I might be an addict lol but I just bought another 50,000 shares 🤗💰

2 · Reply

Tomc73 Oct. 24 at 9:08 PM

$ADAP monday will be good

1 · Reply

Herre62 Oct. 24 at 9:02 PM

$ADAP Have a good weekends , I will catch you guys on premarket on Sunday nights …

1 · Reply

Bottomdog Oct. 24 at 8:53 PM

$ADAP

0 · Reply

stocktraderbegins Oct. 24 at 8:48 PM

$ADAP Are my options done if this hits OTC ?

2 · Reply

maniamedmao Oct. 24 at 8:35 PM

$ADAP I told you so, but bravo to those who believe in poop creating flowers until the end ! You showed determination and I respect that, now if you get equity from this delisting that good bc equity is better than that stocks

0 · Reply

Market Cap	18.55M
Revenue (ttm)	178.03M
Net Income (ttm)	-70.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.77%
Debt to Equity Ratio	-0.36

Volume	47,848,402
Avg Vol	124,226,063
Day's Range	N/A - N/A
Shares Out	265.05M
Stochastic %K	12%
Beta	2.49
Analysts	Hold
Price Target	$0.52